Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dutch company PamGene International has announced the signing of a co-marketing agreement with US-based Invitrogen Corporation for nuclear hormone receptor drug discovery.
Subscribe to our email newsletter
Under the terms of the agreement, Invitrogen and PamGene will co-market Invitrogen’s nuclear hormone receptor proteins and Lanthascreen assay technology with PamGene’s portfolio of microarray-based nuclear hormone receptor screening tools. This is expected to create a complete offering for compound screening in drug discovery in the areas of cancer, diabetes and heart disease.